Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GMED · against 1,336 other Healthcare companies
Ranked #302 of 1,337 · scores higher than 77% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 70–79, including GMED · Click a bar to see the companies
Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | GMED | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 4.9% | 1.5% | 78% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 9.9% | 4.2% | 79% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 7.0% | -1.0% | 88% | 20% | |
| Book yieldHigher is better · 1,306 reported | 44.6% | 37.9% | 57% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 302 | 11.4B CNY (≈$1.6B) | 77 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 50 |
| 302 | 101.2B JPY (≈$688M) | 77 | 54 |
| 302 | 18.3B CNY (≈$2.6B) | 77 | 80 |
| 302 | 1.5B EUR (≈$1.7B) | 77 | 60 |
| 302 | 10.7B USD | 77 | 78 |
| 302 | 1.5B AUD (≈$982M) | 77 | 54 |
| 315 | 22.7B CNY (≈$3.2B) | 76 | 75 |
| 315 | 8.9B CNY (≈$1.2B) | 76 | 62 |
| 315 | 3.4B CNY (≈$472M) | 76 | 56 |